Meropenem on Gram-negative bacteria common clinica

ncycgdxhl · Wysłany: Śro 0:51, 09 Mar 2011

Meropenem on Gram-negative bacteria common clinical drug sensitivity analysis

, Cephalosporins ~ ff Sad

89.33%). 3.4B a lactam antibiotics on the production of ESBL. Strains, according to the National Committee for Clinical Laboratory Standards (NCCSL) provides that: on the production of ESBL. Klebsiella pneumoniae and Escherichia coli may be clinically Penicillium, cephalosporins, or aztreonam treatment ineffective. 3.5 Single-acyl antibiotic aztreonam ring of non-ESBL producing strains have a higher in vitro antibacterial activity against Escherichia coli sensitive to rate of 89.47% for non-ESBL producing Klebsiella pneumoniae sensitive to rate of 93 .33%. 3.6 meropenem than for imipenem of Pseudomonas aeruginosa activity. 75.29% of the sensitivity of Pseudomonas aeruginosa to meropenem, only 67.88% sensitive to imipenem of Pseudomonas aeruginosa; of Acinetobacter baumannii, the highest in vitro antibacterial activity of antibiotics were as follows: United States meropenem (97.26%), imipenem (94.03%) cefepime (89.23%), ceftazidime (89.23%), cefoperazone / sulbactam (88.89%). 4 Discussion enzyme Meropenem is a hydrocarbon vinyl antibiotics,[link widoczny dla zalogowanych], enzymes and other hydrocarbon C1 vinyl in a different methyl, can increase the stability of dehydrogenation peptidase, without combination with enzyme inhibitors, thereby reducing the renal toxicity and central nervous system responses. Meanwhile, in the C2 bit dimethyl disulfide bond aminoacyl pyrrolidine,[link widoczny dla zalogowanych], increase the antibacterial activity against Gram-negative bacteria. This study shows that the middle of Enterobacteriaceae ESBL. Escherichia coli and Klebsiella pneumoniae and non-producing ESBL. Escherichia coli and Klebsiella pneumoniae,[link widoczny dla zalogowanych], meropenem and imipenem in vitro antibacterial activity of the same, sensitivity was 100%, better than the other 16 kinds of antibiotics, and reported the same. Pseudomonas aeruginosa is a common clinical conditions of pathogenic bacteria, but also 591 is the most important pathogens of nosocomial infection is one of the primary lung infection caused by bacteria L6]. The data show that meropenem against Pseudomonas aeruginosa in vitro antimicrobial activity than imipenem. Pseudomonas aeruginosa infection and a variety of therapeutic action, antibiotics and immunosuppressive treatment are closely related, and thus cause a variety of antimicrobial agents. Complex mechanism of resistance of Pseudomonas aeruginosa,[link widoczny dla zalogowanych], mainly produce type I membrane protein permeability cephalosporin reduced enzyme active efflux systems and mechanisms of resistance. Conditions in the past considered to be pathogenic bacteria Acinetobacter baumannii nosocomial infection in recent years has become an important pathogen, the research data of Acinetobacter baumannii, in vitro antibacterial activity of meropenem the most sensitive rate was 97.26 %,[link widoczny dla zalogowanych], better than imipenem and other antibiotics. This study shows that meropenem against Enterobacteriaceae producing ESBLs and non ESBL producing strains have a high antibacterial activity against Pseudomonas aeruginosa, Acinetobacter baumannii in vitro antibacterial activity than imipenem, so the United States meropenem can be used as clinically effective antibiotic treatment of severe infections or suspected pathogen is not clear due to resistant strains of serious infections.